IBDEI1K2 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,25214,1,2,0)
;;=2^96376
;;^UTILITY(U,$J,358.3,25214,1,3,0)
;;=3^Tx/Pro/Dx Inj,ea addl sequential IVP of Same Drug-Add-on
;;^UTILITY(U,$J,358.3,25215,0)
;;=J2680^^91^1143^5^^^^1
;;^UTILITY(U,$J,358.3,25215,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25215,1,2,0)
;;=2^J2680
;;^UTILITY(U,$J,358.3,25215,1,3,0)
;;=3^Fluphenazine Decanoate up to 25mg
;;^UTILITY(U,$J,358.3,25216,0)
;;=J1631^^91^1143^6^^^^1
;;^UTILITY(U,$J,358.3,25216,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25216,1,2,0)
;;=2^J1631
;;^UTILITY(U,$J,358.3,25216,1,3,0)
;;=3^Haloperidol Decanoate per 50mg
;;^UTILITY(U,$J,358.3,25217,0)
;;=J2315^^91^1143^7^^^^1
;;^UTILITY(U,$J,358.3,25217,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25217,1,2,0)
;;=2^J2315
;;^UTILITY(U,$J,358.3,25217,1,3,0)
;;=3^Naltrexone,Depot Form 1mg
;;^UTILITY(U,$J,358.3,25218,0)
;;=J2426^^91^1143^9^^^^1
;;^UTILITY(U,$J,358.3,25218,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25218,1,2,0)
;;=2^J2426
;;^UTILITY(U,$J,358.3,25218,1,3,0)
;;=3^Paliperidone Palmitate Extend Release per 1mg
;;^UTILITY(U,$J,358.3,25219,0)
;;=J2794^^91^1143^10^^^^1
;;^UTILITY(U,$J,358.3,25219,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25219,1,2,0)
;;=2^J2794
;;^UTILITY(U,$J,358.3,25219,1,3,0)
;;=3^Risperidone Long Act per 0.5mg
;;^UTILITY(U,$J,358.3,25220,0)
;;=J2315^^91^1143^11^^^^1
;;^UTILITY(U,$J,358.3,25220,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25220,1,2,0)
;;=2^J2315
;;^UTILITY(U,$J,358.3,25220,1,3,0)
;;=3^Vivitrol 1mg
;;^UTILITY(U,$J,358.3,25221,0)
;;=J0401^^91^1143^1^^^^1
;;^UTILITY(U,$J,358.3,25221,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25221,1,2,0)
;;=2^J0401
;;^UTILITY(U,$J,358.3,25221,1,3,0)
;;=3^Aripiprazole Ext Rel 1mg
;;^UTILITY(U,$J,358.3,25222,0)
;;=J2358^^91^1143^8^^^^1
;;^UTILITY(U,$J,358.3,25222,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25222,1,2,0)
;;=2^J2358
;;^UTILITY(U,$J,358.3,25222,1,3,0)
;;=3^Olanzapine,Long-Acting 1mg
;;^UTILITY(U,$J,358.3,25223,0)
;;=J1943^^91^1143^2^^^^1
;;^UTILITY(U,$J,358.3,25223,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25223,1,2,0)
;;=2^J1943
;;^UTILITY(U,$J,358.3,25223,1,3,0)
;;=3^Aristada Initio 1mg
;;^UTILITY(U,$J,358.3,25224,0)
;;=Q9991^^91^1143^3^^^^1
;;^UTILITY(U,$J,358.3,25224,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25224,1,2,0)
;;=2^Q9991
;;^UTILITY(U,$J,358.3,25224,1,3,0)
;;=3^Buprenorphine Ext-Release (Sublocade),up to 100mg
;;^UTILITY(U,$J,358.3,25225,0)
;;=Q9992^^91^1143^4^^^^1
;;^UTILITY(U,$J,358.3,25225,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25225,1,2,0)
;;=2^Q9992
;;^UTILITY(U,$J,358.3,25225,1,3,0)
;;=3^Buprenorphine Ext-Release (Sublocade) > 100mg
;;^UTILITY(U,$J,358.3,25226,0)
;;=96156^^91^1144^1^^^^1
;;^UTILITY(U,$J,358.3,25226,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25226,1,2,0)
;;=2^96156
;;^UTILITY(U,$J,358.3,25226,1,3,0)
;;=3^Hlth/Behav,Assess/Reassess,Ea 15 min
;;^UTILITY(U,$J,358.3,25227,0)
;;=96158^^91^1144^2^^^^1
;;^UTILITY(U,$J,358.3,25227,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25227,1,2,0)
;;=2^96158
;;^UTILITY(U,$J,358.3,25227,1,3,0)
;;=3^Hlth/Behav Interv,Indiv,Init 30 min
;;^UTILITY(U,$J,358.3,25228,0)
;;=96159^^91^1144^3^^^^1
;;^UTILITY(U,$J,358.3,25228,1,0)
;;=^358.31IA^3^2
;;^UTILITY(U,$J,358.3,25228,1,2,0)
;;=2^96159
;;^UTILITY(U,$J,358.3,25228,1,3,0)
;;=3^Hlth/Behav Interv,Indiv,Ea Addl 15 min
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1K2 3786 printed Apr 09, 2024@20:55:47 Page 2
IBDEI1K2 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,25214,1,2,0)
+2 ;;=2^96376
+3 ;;^UTILITY(U,$J,358.3,25214,1,3,0)
+4 ;;=3^Tx/Pro/Dx Inj,ea addl sequential IVP of Same Drug-Add-on
+5 ;;^UTILITY(U,$J,358.3,25215,0)
+6 ;;=J2680^^91^1143^5^^^^1
+7 ;;^UTILITY(U,$J,358.3,25215,1,0)
+8 ;;=^358.31IA^3^2
+9 ;;^UTILITY(U,$J,358.3,25215,1,2,0)
+10 ;;=2^J2680
+11 ;;^UTILITY(U,$J,358.3,25215,1,3,0)
+12 ;;=3^Fluphenazine Decanoate up to 25mg
+13 ;;^UTILITY(U,$J,358.3,25216,0)
+14 ;;=J1631^^91^1143^6^^^^1
+15 ;;^UTILITY(U,$J,358.3,25216,1,0)
+16 ;;=^358.31IA^3^2
+17 ;;^UTILITY(U,$J,358.3,25216,1,2,0)
+18 ;;=2^J1631
+19 ;;^UTILITY(U,$J,358.3,25216,1,3,0)
+20 ;;=3^Haloperidol Decanoate per 50mg
+21 ;;^UTILITY(U,$J,358.3,25217,0)
+22 ;;=J2315^^91^1143^7^^^^1
+23 ;;^UTILITY(U,$J,358.3,25217,1,0)
+24 ;;=^358.31IA^3^2
+25 ;;^UTILITY(U,$J,358.3,25217,1,2,0)
+26 ;;=2^J2315
+27 ;;^UTILITY(U,$J,358.3,25217,1,3,0)
+28 ;;=3^Naltrexone,Depot Form 1mg
+29 ;;^UTILITY(U,$J,358.3,25218,0)
+30 ;;=J2426^^91^1143^9^^^^1
+31 ;;^UTILITY(U,$J,358.3,25218,1,0)
+32 ;;=^358.31IA^3^2
+33 ;;^UTILITY(U,$J,358.3,25218,1,2,0)
+34 ;;=2^J2426
+35 ;;^UTILITY(U,$J,358.3,25218,1,3,0)
+36 ;;=3^Paliperidone Palmitate Extend Release per 1mg
+37 ;;^UTILITY(U,$J,358.3,25219,0)
+38 ;;=J2794^^91^1143^10^^^^1
+39 ;;^UTILITY(U,$J,358.3,25219,1,0)
+40 ;;=^358.31IA^3^2
+41 ;;^UTILITY(U,$J,358.3,25219,1,2,0)
+42 ;;=2^J2794
+43 ;;^UTILITY(U,$J,358.3,25219,1,3,0)
+44 ;;=3^Risperidone Long Act per 0.5mg
+45 ;;^UTILITY(U,$J,358.3,25220,0)
+46 ;;=J2315^^91^1143^11^^^^1
+47 ;;^UTILITY(U,$J,358.3,25220,1,0)
+48 ;;=^358.31IA^3^2
+49 ;;^UTILITY(U,$J,358.3,25220,1,2,0)
+50 ;;=2^J2315
+51 ;;^UTILITY(U,$J,358.3,25220,1,3,0)
+52 ;;=3^Vivitrol 1mg
+53 ;;^UTILITY(U,$J,358.3,25221,0)
+54 ;;=J0401^^91^1143^1^^^^1
+55 ;;^UTILITY(U,$J,358.3,25221,1,0)
+56 ;;=^358.31IA^3^2
+57 ;;^UTILITY(U,$J,358.3,25221,1,2,0)
+58 ;;=2^J0401
+59 ;;^UTILITY(U,$J,358.3,25221,1,3,0)
+60 ;;=3^Aripiprazole Ext Rel 1mg
+61 ;;^UTILITY(U,$J,358.3,25222,0)
+62 ;;=J2358^^91^1143^8^^^^1
+63 ;;^UTILITY(U,$J,358.3,25222,1,0)
+64 ;;=^358.31IA^3^2
+65 ;;^UTILITY(U,$J,358.3,25222,1,2,0)
+66 ;;=2^J2358
+67 ;;^UTILITY(U,$J,358.3,25222,1,3,0)
+68 ;;=3^Olanzapine,Long-Acting 1mg
+69 ;;^UTILITY(U,$J,358.3,25223,0)
+70 ;;=J1943^^91^1143^2^^^^1
+71 ;;^UTILITY(U,$J,358.3,25223,1,0)
+72 ;;=^358.31IA^3^2
+73 ;;^UTILITY(U,$J,358.3,25223,1,2,0)
+74 ;;=2^J1943
+75 ;;^UTILITY(U,$J,358.3,25223,1,3,0)
+76 ;;=3^Aristada Initio 1mg
+77 ;;^UTILITY(U,$J,358.3,25224,0)
+78 ;;=Q9991^^91^1143^3^^^^1
+79 ;;^UTILITY(U,$J,358.3,25224,1,0)
+80 ;;=^358.31IA^3^2
+81 ;;^UTILITY(U,$J,358.3,25224,1,2,0)
+82 ;;=2^Q9991
+83 ;;^UTILITY(U,$J,358.3,25224,1,3,0)
+84 ;;=3^Buprenorphine Ext-Release (Sublocade),up to 100mg
+85 ;;^UTILITY(U,$J,358.3,25225,0)
+86 ;;=Q9992^^91^1143^4^^^^1
+87 ;;^UTILITY(U,$J,358.3,25225,1,0)
+88 ;;=^358.31IA^3^2
+89 ;;^UTILITY(U,$J,358.3,25225,1,2,0)
+90 ;;=2^Q9992
+91 ;;^UTILITY(U,$J,358.3,25225,1,3,0)
+92 ;;=3^Buprenorphine Ext-Release (Sublocade) > 100mg
+93 ;;^UTILITY(U,$J,358.3,25226,0)
+94 ;;=96156^^91^1144^1^^^^1
+95 ;;^UTILITY(U,$J,358.3,25226,1,0)
+96 ;;=^358.31IA^3^2
+97 ;;^UTILITY(U,$J,358.3,25226,1,2,0)
+98 ;;=2^96156
+99 ;;^UTILITY(U,$J,358.3,25226,1,3,0)
+100 ;;=3^Hlth/Behav,Assess/Reassess,Ea 15 min
+101 ;;^UTILITY(U,$J,358.3,25227,0)
+102 ;;=96158^^91^1144^2^^^^1
+103 ;;^UTILITY(U,$J,358.3,25227,1,0)
+104 ;;=^358.31IA^3^2
+105 ;;^UTILITY(U,$J,358.3,25227,1,2,0)
+106 ;;=2^96158
+107 ;;^UTILITY(U,$J,358.3,25227,1,3,0)
+108 ;;=3^Hlth/Behav Interv,Indiv,Init 30 min
+109 ;;^UTILITY(U,$J,358.3,25228,0)
+110 ;;=96159^^91^1144^3^^^^1
+111 ;;^UTILITY(U,$J,358.3,25228,1,0)
+112 ;;=^358.31IA^3^2
+113 ;;^UTILITY(U,$J,358.3,25228,1,2,0)
+114 ;;=2^96159
+115 ;;^UTILITY(U,$J,358.3,25228,1,3,0)
+116 ;;=3^Hlth/Behav Interv,Indiv,Ea Addl 15 min
